EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China

Yingyi Guo, Likang Yao, Jiong Wang, Yan Zhang, Chuyue Zhuo, Yijing Wang, Xu Yang, Jiahui Li, Nanhao He, Jiakang Chen, Yexin Lin, Shunian Xiao und 2 weitere

Infection · 2025

DOI: 10.1007/s15010-025-02474-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Infection, 2025. Verfasst von Yingyi Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: High-level Scientific Research Project of People's Hospital of Yangjiang, the State Key Project of Research and Development Plan, High-level Scientific Research Project of People’s Hospital of Yangjiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ceftazidime-avibactam (CAZ-AVI) and imipenem-relebactam (IMI-REL) are both antibiotics with promising prospects for treating Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. However, differences in the in vitro activities and resistance mechanisms to CAZ-AVI and IMI-REL in clinical KPC-Kps have not been described. METHODS: In this study, KPC-Kp isolates from hospitalized patients in China were collected and subjected to antimicrobial susceptibility testing of IMI-REL and CAZ-AVI using the broth microdilution method. Whole-genome sequencing (WGS) and functional validation of mutations were performed on resistant strains, and RT-qPCR was used to determine the expression levels of blaKPC. RESULTS: The results showed that 21 (2.7%) of 782 clinical KPC-Kp strains were CAZ-AVI-resistant, 6 (0.8%) of 782 strains were IMI-REL-resistant, and 5 strains among them were resistant to both CAZ-AVI and IMI-REL. Strains resistant to both CAZ-AVI and IMI-REL can be effectively inhibited by tigecycline and polymyxin B. WGS and complementation experiments showed that KPC mutations are linked to high-level resistance to CAZ-AVI; while OmpK36 mutations may be the vital mechanism of IMI-REL resistance, confers resistance to CAZ-AVI simultaneously. Furthermore, RT-qPCR indicated that elevated blaKPC expression may play an important role in both CAZ-AVI and IMI-REL resistance. CONCLUSIONS: In summary, this study suggested that IMI-REL may have superior inhibitory effects in vitro on KPC-Kps than CAZ-AVI, and described the differences in resistance mechanisms between the two antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeCeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsImipenemKlebsiella InfectionsDrug Resistance, Multiple, BacterialHumansChinaDrug CombinationsMicrobial Sensitivity Testsbeta-LactamasesBacterial ProteinsWhole Genome Sequencing

Stichwörter der Autor:innen

Klebsiella pneumoniaeCeftazidime–avibactamImipenem–relebactamResistance

Substanzen

Ceftazidimeavibactam, ceftazidime drug combinationAzabicyclo CompoundsAnti-Bacterial AgentsImipenemDrug Combinationsbeta-LactamasesBacterial Proteinsrelebactamcarbapenemase

Autor:innen und Institutionen

  • The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China.
  • State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital…
  • The Medical Laboratory Department, Huadu District People's Hospital of Guangzhou, Guangzhou, China.
  • Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, China.
  • State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
  • Laboratory of Respiratory Disease, People's Hospital of Yangjiang, Guangdong, China. 422156321@qq.com.

Förderung

  • High-level Scientific Research Project of People's Hospital of Yangjiang
  • the State Key Project of Research and Development Plan
  • High-level Scientific Research Project of People’s Hospital of Yangjiang

Zitieren

APA

Guo, Y., Yao, L., Wang, J., Zhang, Y., Zhuo, C., Wang, Y., Yang, X., Li, J., He, N., Chen, J., Lin, Y., Xiao, S., Lin, Z., & Zhuo, C. (2025). Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China. Infection. https://doi.org/10.1007/s15010-025-02474-3

Vancouver

Guo Y, Yao L, Wang J, Zhang Y, Zhuo C, Wang Y, et al. Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China. Infection. 2025. doi:10.1007/s15010-025-02474-3

BibTeX
@article{Guo2025,
  author = {Guo, Yingyi and Yao, Likang and Wang, Jiong and Zhang, Yan and Zhuo, Chuyue and Wang, Yijing and Yang, Xu and Li, Jiahui and He, Nanhao and Chen, Jiakang and Lin, Yexin and Xiao, Shunian and Lin, Zhiwei and Zhuo, Chao},
  title = {Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China},
  journal = {Infection},
  year = {2025},
  doi = {10.1007/s15010-025-02474-3}
}
Kostenlos starten →